Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-annual vs Once-annual Influenza Vaccination in Older Adults (RETAIN)
NCT02957890Phase 4Active, not recruiting
- Sponsor
- The University of Hong Kong
- Start
- Nov 2016
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Fluzone Trivalent in influenza (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Antibody titres measured by haemagglutination-inhibition assays at 182 days. Started Nov 2016; status: active, not recruiting.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02957890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957890.